Soligenix (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach
Austin, Texas, United States, April 21st, 2026, FinanceWire By Christopher J. Schaber, chairman, president, and CEO, Soligenix; published via Clinical Leader Soligenix (NASDAQ: […]








